# Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)

> **NCT01902966** · NA · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Propranolol
- **BEHAVIORAL:** Diary
- **BEHAVIORAL:** Relaxation Audio Recording
- **BEHAVIORAL:** Questionnaires

## Key facts

- **NCT ID:** NCT01902966
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09-11
- **Primary completion:** 2020-08-14
- **Final completion:** 2020-08-14
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** low accrual and lack of funding
- **Last updated:** 2021-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01902966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01902966, "Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01902966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*